ANAB · NASDAQ
AnaptysBio, Inc.
$48.50 -0.10 (-0.21%)
Company overview
AnaptysBio, Inc., a clinical-stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell-driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaboration and license agreements with GlaxoSmithKline, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.4B
- Employees
- 104
- Headquarters
- San Diego, CA
- Website
- anaptysbio.com
- CEO
- Daniel Faga
- Listed
- January 26, 2017
- P/E
- -57.06
- Dividend yield
- 0.00%
Company financials
- Revenue
- $232M
- Gross profit
- $271M
- Operating income
- $40.8M
- EBITDA
- $53.3M
- Net income
- -$26.8M
- EPS
- -$0.85
- Total assets
- $330M
- Total debt
- $277M
- Gross margin
- 116.42%
- Net margin
- -11.53%
- Earnings yield
- -1.75%
No annual segmentation.
No geographic segmentation.
ANAB
1D
NASDAQ
O50.34H50.99L48.47C48.60-1.90 (-3.76%)Vol87.11K